0 XP   0   0   0

Vyant Bio Inc
Buy, Hold or Sell?

Should you buy, hold or sell Vyant Bio Inc?

I guess you are interested in Vyant Bio Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Vyant Bio Inc

Let's start. I'm going to help you getting a better view of Vyant Bio Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is Vyant Bio Inc even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how Vyant Bio Inc is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Vyant Bio Inc. The closing price on 2023-01-27 was $0.9225 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
Vyant Bio Inc Daily Candlestick Chart
Vyant Bio Inc Daily Candlestick Chart
Summary









1. Valuation of Vyant Bio Inc




Current price per share

$0.92

2. Growth of Vyant Bio Inc




Is Vyant Bio Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$13.8m$45.7m-$24.6m-117.2%

How much money is Vyant Bio Inc making?

Current yearPrevious yearGrowGrow %
Making money-$10.8m-$4m-$6.8m-63.0%
Net Profit Margin-1,959.3%-957.4%--

How much money comes from the company's main activities?

3. Financial Health of Vyant Bio Inc




Comparing to competitors in the Biotechnology industry




  Industry Rankings (Biotechnology)  


Richest
#894 / 1232

Most Revenue
#1220 / 1232

Most Profit
#637 / 1232

Most Efficient
#1008 / 1232


Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

1.1. Profitability of Vyant Bio Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Vyant Bio Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Vyant Bio Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -2,278.3% means that $-22.78 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Vyant Bio Inc:

  • The MRQ is -2,278.3%. The company is making a huge loss. -2
  • The TTM is -1,959.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-2,278.3%TTM-1,959.3%-319.0%
TTM-1,959.3%YOY-957.4%-1,002.0%
TTM-1,959.3%5Y-628.5%-1,330.9%
5Y-628.5%10Y-379.4%-249.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2,278.3%-223.6%-2,054.7%
TTM-1,959.3%-281.7%-1,677.6%
YOY-957.4%-344.8%-612.6%
5Y-628.5%-450.1%-178.4%
10Y-379.4%-541.0%+161.6%
1.1.2. Return on Assets

Shows how efficient Vyant Bio Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Vyant Bio Inc to the Biotechnology industry mean.
  • -15.0% Return on Assets means that Vyant Bio Inc generated $-0.15 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Vyant Bio Inc:

  • The MRQ is -15.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -32.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-15.0%TTM-32.7%+17.7%
TTM-32.7%YOY-6.0%-26.7%
TTM-32.7%5Y-13.5%-19.2%
5Y-13.5%10Y-14.2%+0.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-15.0%-9.9%-5.1%
TTM-32.7%-8.9%-23.8%
YOY-6.0%-9.3%+3.3%
5Y-13.5%-11.7%-1.8%
10Y-14.2%-12.7%-1.5%
1.1.3. Return on Equity

Shows how efficient Vyant Bio Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Vyant Bio Inc to the Biotechnology industry mean.
  • -25.0% Return on Equity means Vyant Bio Inc generated $-0.25 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Vyant Bio Inc:

  • The MRQ is -25.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -45.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-25.0%TTM-45.0%+20.0%
TTM-45.0%YOY-6.6%-38.4%
TTM-45.0%5Y-29.5%-15.5%
5Y-29.5%10Y-22.9%-6.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-25.0%-12.0%-13.0%
TTM-45.0%-11.5%-33.5%
YOY-6.6%-10.8%+4.2%
5Y-29.5%-14.2%-15.3%
10Y-22.9%-15.2%-7.7%

1.2. Operating Efficiency of Vyant Bio Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Vyant Bio Inc is operating .

  • Measures how much profit Vyant Bio Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Vyant Bio Inc to the Biotechnology industry mean.
  • An Operating Margin of -2,259.2% means the company generated $-22.59  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Vyant Bio Inc:

  • The MRQ is -2,259.2%. The company is operating very inefficient. -2
  • The TTM is -1,952.1%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-2,259.2%TTM-1,952.1%-307.2%
TTM-1,952.1%YOY-916.3%-1,035.8%
TTM-1,952.1%5Y-616.1%-1,336.0%
5Y-616.1%10Y-373.2%-242.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2,259.2%-207.3%-2,051.9%
TTM-1,952.1%-271.0%-1,681.1%
YOY-916.3%-325.9%-590.4%
5Y-616.1%-454.0%-162.1%
10Y-373.2%-537.1%+163.9%
1.2.2. Operating Ratio

Measures how efficient Vyant Bio Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 25.22 means that the operating costs are $25.22 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Vyant Bio Inc:

  • The MRQ is 25.217. The company is inefficient in keeping operating costs low. -1
  • The TTM is 16.992. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ25.217TTM16.992+8.225
TTM16.992YOY5.663+11.328
TTM16.9925Y5.525+11.467
5Y5.52510Y3.897+1.628
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ25.2172.871+22.346
TTM16.9923.504+13.488
YOY5.6633.604+2.059
5Y5.5255.132+0.393
10Y3.8976.371-2.474

1.3. Liquidity of Vyant Bio Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Vyant Bio Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.81 means the company has $1.81 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Vyant Bio Inc:

  • The MRQ is 1.812. The company is able to pay all its short-term debts. +1
  • The TTM is 2.747. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.812TTM2.747-0.936
TTM2.747YOY4.443-1.695
TTM2.7475Y1.906+0.841
5Y1.90610Y3.387-1.481
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8125.117-3.305
TTM2.7475.755-3.008
YOY4.4435.854-1.411
5Y1.9066.511-4.605
10Y3.3876.222-2.835
1.3.2. Quick Ratio

Measures if Vyant Bio Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Vyant Bio Inc to the Biotechnology industry mean.
  • A Quick Ratio of 1.46 means the company can pay off $1.46 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Vyant Bio Inc:

  • The MRQ is 1.461. The company is able to pay all its short-term debts with the most liquid assets. +1
  • The TTM is 2.309. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.461TTM2.309-0.848
TTM2.309YOY4.082-1.773
TTM2.3095Y1.567+0.742
5Y1.56710Y3.104-1.537
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4614.284-2.823
TTM2.3094.664-2.355
YOY4.0824.787-0.705
5Y1.5675.218-3.651
10Y3.1045.182-2.078

1.4. Solvency of Vyant Bio Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Vyant Bio Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Vyant Bio Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.40 means that Vyant Bio Inc assets are financed with 39.9% credit (debt) and the remaining percentage (100% - 39.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Vyant Bio Inc:

  • The MRQ is 0.399. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.314. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.399TTM0.314+0.086
TTM0.314YOY0.216+0.097
TTM0.3145Y0.482-0.169
5Y0.48210Y0.555-0.072
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3990.278+0.121
TTM0.3140.277+0.037
YOY0.2160.306-0.090
5Y0.4820.367+0.115
10Y0.5550.403+0.152
1.4.2. Debt to Equity Ratio

Measures if Vyant Bio Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Vyant Bio Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 66.5% means that company has $0.66 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Vyant Bio Inc:

  • The MRQ is 0.665. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.480. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.665TTM0.480+0.185
TTM0.480YOY0.353+0.126
TTM0.4805Y1.488-1.008
5Y1.48810Y1.036+0.452
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6650.315+0.350
TTM0.4800.317+0.163
YOY0.3530.319+0.034
5Y1.4880.403+1.085
10Y1.0360.462+0.574

2. Market Valuation of Vyant Bio Inc

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Vyant Bio Inc generates.

  • Above 15 is considered overpriced but always compare Vyant Bio Inc to the Biotechnology industry mean.
  • A PE ratio of -0.95 means the investor is paying $-0.95 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Vyant Bio Inc:

  • The EOD is -1.574. Company is losing money. -2
  • The MRQ is -0.952. Company is losing money. -2
  • The TTM is -0.918. Company is losing money. -2
Trends
Current periodCompared to+/- 
EOD-1.574MRQ-0.952-0.622
MRQ-0.952TTM-0.918-0.034
TTM-0.918YOY-9.709+8.791
TTM-0.9185Y-4.690+3.772
5Y-4.69010Y-8.386+3.696
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.574-8.986+7.412
MRQ-0.952-9.792+8.840
TTM-0.918-16.243+15.325
YOY-9.709-20.876+11.167
5Y-4.690-16.665+11.975
10Y-8.386-14.732+6.346
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Vyant Bio Inc.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Vyant Bio Inc:

  • The MRQ is -0.679. Very Bad. -2
  • The TTM is 3.460. Seems overpriced? -1
Trends
Current periodCompared to+/- 
MRQ-0.679TTM3.460-4.138
TTM3.460YOY-3.499+6.959
TTM3.4605Y-2.950+6.410
5Y-2.95010Y-7.419+4.468
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.679-0.032-0.647
TTM3.4600.004+3.456
YOY-3.4990.016-3.515
5Y-2.9500.006-2.956
10Y-7.4190.003-7.422

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Vyant Bio Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.24 means the investor is paying $0.24 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Vyant Bio Inc:

  • The EOD is 0.394. Very good. +2
  • The MRQ is 0.238. Very good. +2
  • The TTM is 0.298. Very good. +2
Trends
Current periodCompared to+/- 
EOD0.394MRQ0.238+0.156
MRQ0.238TTM0.298-0.060
TTM0.298YOY1.914-1.616
TTM0.2985Y1.343-1.046
5Y1.34310Y1.595-0.252
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.3941.835-1.441
MRQ0.2382.006-1.768
TTM0.2982.774-2.476
YOY1.9143.453-1.539
5Y1.3432.713-1.370
10Y1.5952.402-0.807
2. Total Gains per Share

2.4. Latest News of Vyant Bio Inc

Does Vyant Bio Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Vyant Bio Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2023-01-04
22:15
Vyant Bio Engages LifeSci Capital to Explore Strategic AlternativesRead

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Vyant Bio Inc.

3.1. Institutions holding Vyant Bio Inc

Institutions are holding 7.654% of the shares of Vyant Bio Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2022-06-30Vanguard Group Inc2.5609075679900
2022-06-30Frontier Wealth Management, LLC0.68560.013420260100
2022-06-30Geode Capital Management, LLC0.6585019458657843.0635
2022-06-30State Street Corporation0.254507520032004.4444
2022-06-30Northern Trust Corp0.148604390100
2022-09-30JACKSON SQUARE CAPITAL, LLC0.10280.00833038900
2022-06-30Virtu Financial LLC0.08670.00225611256110
2022-06-30U.S. Bancorp0.08402481300
2022-09-30CAMBRIDGE Invest RESEARCH ADVISORS, INC.0.07260.000121460214600
2022-06-30Renaissance Technologies Corp0.06870203008904.5853
2022-06-30Morgan Stanley - Brokerage Accounts0.0678020049-22-0.1096
2022-06-30NorthRock Partners LLC0.06370.00181883200
2022-06-30UBS Group AG0.059017437814887.7167
2022-09-30AE Wealth Management LLC0.04710.00011393300
2022-06-30Carlson Capital Management Inc0.03990.0011180000
2022-06-30Taylor Wealth Management Partners0.03480.005110273-3424-24.9982
2022-06-30Wells Fargo & Co0.000601791710.4938
2022-06-30CapTrust Financial Advisors0.0002050-74-59.6774
2022-06-30FMR Inc0.0001021210
2022-06-30Barclays PLC0.000101500
Total 5.03620.03181488249+61611+4.1%

3.2. Funds holding Vyant Bio Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2022-09-30Vanguard Instl Ttl Stck Mkt Idx Tr1.7373051341200
2022-10-31Fidelity® Extended Market Index0.38540.0002113884-179-0.1569
2022-11-30Vanguard Total Stock Mkt Idx Inv1.7373010268200
2022-11-30Vanguard Extended Market Index Investor0.71140.00014204600
2022-10-31Fidelity® Series Total Market Index0.104303081800
2022-09-30NT Ext Equity Mkt Idx Fd - NL0.07840.00032317400
2022-09-30Northern Trust Extended Eq Market Idx0.06960.00032056100
2022-09-30NT Ext Equity Mkt Idx Fd - L0.06960.00032056100
2022-10-31Fidelity® NASDAQ Composite Index®0.06670.00011971700
2022-09-30NT Ext Equity Mkt Idx Fd - DC - NL - T20.06320.0003186872491.3505
2022-10-31Fidelity® Total Market Index0.060901800700
2022-09-30SSgA U.S. Extended Market Index Class I0.02910.0002859900
2022-10-31Spartan Total Market Index Pool E0.0280827300
2022-02-28The Vanguard Total Stock Market Index0.02140.0001632900
2022-11-30Vanguard Instl Ttl Stk Mkt Idx InstlPls0.06960411500
2022-10-31Spartan Extended Market Index Pool E0.01320.000238871794.8274
2022-09-30USAA Extended Market Index0.00960.00022830-353-11.0902
2022-09-30SSgA U.S. Total Market Index Strategy0.0090266280.3014
2022-11-30Vanguard U.S. Eq Idx £ Acc0.04260251600
2022-11-30State St US Extended Mkt Indx NL Cl C0.02910.00011719-1-0.0581
Total 5.33570.0024964479-970.0%

3.3. Insider Transactions

Insiders are holding 24.843% of the shares of Vyant Bio Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2021-12-06Marcus BoehmBUY50001.69
2021-11-24John A RobertsBUY50002.02
2021-11-22Yung-ping YehBUY5002.05
2021-10-27Marcus BoehmBUY50002.1
2021-09-29Marcus BoehmBUY50002.44
2021-08-25Marcus BoehmBUY50002.58
2021-08-25Yung-ping YehBUY10002.6412262
2021-08-23John A RobertsBUY104062.41
2021-08-19Paul R HansenBUY200002.35
2021-07-28Marcus BoehmBUY50002.92
2021-05-28Marcus BoehmBUY50003.6898929
2021-05-26John A RobertsBUY70413.55305076
2021-05-24John A RobertsBUY74403.38305076
2021-05-24R John FletcherBUY303003.36 
2019-01-31John A RobertsBUY1854360.23297636
2019-01-31John PappajohnBUY10000000.234781204
2019-01-31Michael Glenn MilesBUY1500000.23150000
2019-01-14John A RobertsBUY1000000.23112200
2019-01-14John PappajohnBUY10000000.233781204
2017-12-15John A RobertsBUY12200212200

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Vyant Bio Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.499-1.780+257%2.162-123%-0.146-71%0.147-438%
Book Value Growth--0.8240.712+16%5.680-85%1.810-54%1.687-51%
Book Value Per Share--2.3423.565-34%5.719-59%2.963-21%3.573-34%
Book Value Per Share Growth--0.8240.712+16%6.402-87%1.955-58%1.761-53%
Current Ratio--1.8122.747-34%4.443-59%1.906-5%3.387-47%
Debt To Asset Ratio--0.3990.314+27%0.216+85%0.482-17%0.555-28%
Debt To Equity Ratio--0.6650.480+39%0.353+88%1.488-55%1.036-36%
Dividend Per Share----0%-0%-0%-0%
Eps---0.586-1.167+99%-0.649+11%-0.785+34%-0.741+26%
Eps Growth--1.4030.929+51%-0.275+120%0.147+854%0.409+243%
Free Cash Flow Per Share---0.423-0.593+40%-0.449+6%-0.438+3%-0.515+22%
Free Cash Flow Per Share Growth--1.4431.021+41%0.246+488%0.738+95%0.656+120%
Free Cash Flow To Equity Per Share---0.390-0.578+48%-0.035-91%-0.216-44%-0.036-91%
Free Cash Flow To Equity Per Share Growth--1.5090.995+52%0.773+95%-0.354+123%-0.154+110%
Gross Profit Margin--1.4571.114+31%19.157-92%4.855-70%3.132-53%
Intrinsic Value_10Y_max--2.117--------
Intrinsic Value_10Y_min---35.193--------
Intrinsic Value_1Y_max---1.622--------
Intrinsic Value_1Y_min---2.584--------
Intrinsic Value_3Y_max---3.477--------
Intrinsic Value_3Y_min---8.626--------
Intrinsic Value_5Y_max---3.645--------
Intrinsic Value_5Y_min---15.567--------
Net Profit Margin---22.783-19.593-14%-9.574-58%-6.285-72%-3.794-83%
Operating Margin---22.592-19.521-14%-9.163-59%-6.161-73%-3.732-83%
Operating Ratio--25.21716.992+48%5.663+345%5.525+356%3.897+547%
Pb Ratio0.394+40%0.2380.298-20%1.914-88%1.343-82%1.595-85%
Pe Ratio-1.574-65%-0.952-0.918-4%-9.709+919%-4.690+392%-8.386+781%
Peg Ratio---0.6793.460-120%-3.499+416%-2.950+335%-7.419+993%
Price Per Share0.923+40%0.5581.062-47%3.370-83%1.990-72%4.493-88%
Price To Total Gains Ratio-1.850-65%-1.119-0.839-25%-2.409+115%-32.604+2813%-19.842+1673%
Profit Growth--1.4030.208+575%-487.000+34800%-97.556+7051%-49.511+3628%
Quick Ratio--1.4612.309-37%4.082-64%1.567-7%3.104-53%
Return On Assets---0.150-0.327+118%-0.060-60%-0.135-10%-0.142-6%
Return On Equity---0.250-0.450+80%-0.066-73%-0.295+18%-0.229-8%
Revenue Growth--0.9210.477+93%2.637-65%1.183-22%1.158-20%
Total Gains Per Share---0.499-1.780+257%2.162-123%-0.146-71%0.147-438%
Total Gains Per Share Growth--1.4720.980+50%9.364-84%3.239-55%2.458-40%
Usd Book Value--13840000.00021071250.000-34%45757750.000-70%19902900.000-30%22342981.923-38%
Usd Book Value Change Per Share---0.499-1.780+257%2.162-123%-0.146-71%0.147-438%
Usd Book Value Per Share--2.3423.565-34%5.719-59%2.963-21%3.573-34%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.586-1.167+99%-0.649+11%-0.785+34%-0.741+26%
Usd Free Cash Flow---2501000.000-3503500.000+40%-3961750.000+58%-2848300.000+14%-3178189.769+27%
Usd Free Cash Flow Per Share---0.423-0.593+40%-0.449+6%-0.438+3%-0.515+22%
Usd Free Cash Flow To Equity Per Share---0.390-0.578+48%-0.035-91%-0.216-44%-0.036-91%
Usd Price Per Share0.923+40%0.5581.062-47%3.370-83%1.990-72%4.493-88%
Usd Profit---3463000.000-10819250.000+212%-4004192.250+16%-5010738.450+45%-4569134.256+32%
Usd Revenue--152000.000-476750.000+414%1246500.000-88%2757050.000-94%3554803.692-96%
Usd Total Gains Per Share---0.499-1.780+257%2.162-123%-0.146-71%0.147-438%
 EOD+2 -3MRQTTM+28 -12YOY+13 -275Y+16 -2410Y+15 -25

4.2. Fundamental Score

Let's check the fundamental score of Vyant Bio Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.574
Price to Book Ratio (EOD)Between0-10.394
Net Profit Margin (MRQ)Greater than0-22.783
Operating Margin (MRQ)Greater than0-22.592
Quick Ratio (MRQ)Greater than11.461
Current Ratio (MRQ)Greater than11.812
Debt to Asset Ratio (MRQ)Less than10.399
Debt to Equity Ratio (MRQ)Less than10.665
Return on Equity (MRQ)Greater than0.15-0.250
Return on Assets (MRQ)Greater than0.05-0.150
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of Vyant Bio Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.899
Total0/1 (0.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2021-09-302021-12-312022-03-312022-06-302022-09-30
Discontinued Operations  -4,7570-4,7570-4,7573,277-1,4801,664184



Latest Balance Sheet

Balance Sheet of 2022-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets23,039
Total Liabilities9,199
Total Stockholder Equity13,840
 As reported
Total Liabilities 9,199
Total Stockholder Equity+ 13,840
Total Assets = 23,039

Assets

Total Assets23,039
Total Current Assets12,126
Long-term Assets12,126
Total Current Assets
Cash And Cash Equivalents 9,394
Net Receivables 383
Inventory 66
Other Current Assets 2,283
Total Current Assets  (as reported)12,126
Total Current Assets  (calculated)12,126
+/-0
Long-term Assets
Property Plant Equipment 2,840
Other Assets 8,073
Long-term Assets  (as reported)10,913
Long-term Assets  (calculated)10,913
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities6,693
Long-term Liabilities2,506
Total Stockholder Equity13,840
Total Current Liabilities
Short-term Debt 550
Accounts payable 897
Other Current Liabilities 5,174
Total Current Liabilities  (as reported)6,693
Total Current Liabilities  (calculated)6,621
+/- 72
Long-term Liabilities
Long term Debt 57
Capital Lease Obligations Min Short Term Debt1,721
Other Liabilities 728
Long-term Liabilities  (as reported)2,506
Long-term Liabilities  (calculated)2,506
+/-0
Total Stockholder Equity
Common Stock1
Retained Earnings -97,244
Accumulated Other Comprehensive Income 74
Other Stockholders Equity 111,009
Total Stockholder Equity (as reported)13,840
Total Stockholder Equity (calculated)13,840
+/-0
Other
Capital Stock1
Cash and Short Term Investments 9,394
Common Stock Shares Outstanding 5,883
Current Deferred Revenue72
Liabilities and Stockholders Equity 23,039
Net Debt -7,066
Net Invested Capital 13,897
Net Tangible Assets 13,840
Net Working Capital 5,433
Short Long Term Debt Total 2,328



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-03-312010-12-31
> Total Assets 
5,302
0
4,108
7,031
8,366
7,389
7,938
8,952
7,411
6,456
14,307
55,157
53,084
49,599
51,633
47,105
43,195
39,828
35,980
48,884
43,969
44,235
45,823
42,434
43,365
40,949
53,970
52,221
52,221
41,371
39,885
35,406
35,406
37,115
20,836
14,904
14,904
11,788
9,690
7,532
72,355
65,401
61,220
37,636
32,529
26,811
23,039
23,03926,81132,52937,63661,22065,40172,3557,5329,69011,78814,90414,90420,83637,11535,40635,40639,88541,37152,22152,22153,97040,94943,36542,43445,82344,23543,96948,88435,98039,82843,19547,10551,63349,59953,08455,15714,3076,4567,4118,9527,9387,3898,3667,0314,10805,302
   > Total Current Assets 
3,306
0
1,159
3,376
3,206
1,613
2,195
2,160
1,940
3,913
12,207
51,891
44,063
40,693
36,018
31,774
28,286
31,096
26,624
28,198
23,545
24,466
26,580
23,424
24,357
21,869
23,485
23,206
23,206
14,203
13,115
9,347
9,347
26,554
12,603
7,178
7,178
4,622
2,801
4,107
36,541
30,073
26,294
23,214
20,464
16,248
12,126
12,12616,24820,46423,21426,29430,07336,5414,1072,8014,6227,1787,17812,60326,5549,3479,34713,11514,20323,20623,20623,48521,86924,35723,42426,58024,46623,54528,19826,62431,09628,28631,77436,01840,69344,06351,89112,2073,9131,9402,1602,1951,6133,2063,3761,15903,306
       Cash And Cash Equivalents 
1,779
0
193
2,417
2,034
402
903
820
217
1,941
9,878
49,460
41,315
37,418
30,748
25,554
22,312
23,744
19,918
19,459
13,273
10,552
10,716
9,502
9,664
6,170
4,807
9,541
9,541
1,601
1,206
161
161
667
2,147
3,880
3,880
2,864
1,133
2,444
33,074
26,485
23,203
20,608
16,440
11,702
9,394
9,39411,70216,44020,60823,20326,48533,0742,4441,1332,8643,8803,8802,1476671611611,2061,6019,5419,5414,8076,1709,6649,50210,71610,55213,27319,45919,91823,74422,31225,55430,74837,41841,31549,4609,8781,9412178209034022,0342,41719301,779
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
56
0
0
0
0
0
0
0
0
000000005600000000000000000000000000000000000000
       Net Receivables 
706
0
693
689
750
737
839
851
1,125
1,263
1,616
1,639
1,818
2,056
4,109
5,029
4,824
5,723
5,165
6,621
8,449
11,944
13,679
11,748
12,675
13,155
15,797
10,958
10,958
9,357
8,981
7,038
7,038
691
7,608
1,584
1,584
611
773
779
924
1,261
1,192
434
585
484
383
3834845854341,1921,2619247797736111,5841,5847,6086917,0387,0388,9819,35710,95810,95815,79713,15512,67511,74813,67911,9448,4496,6215,1655,7234,8245,0294,1092,0561,8181,6391,6161,2631,1258518397377506896930706
       Other Current Assets 
821
0
274
66
422
475
452
256
599
709
713
594
929
1,219
1,162
911
1,149
1,629
1,541
1,985
1,823
1,970
2,185
2,028
2,018
2,544
2,881
0
873
3,245
2,928
0
710
25,196
2,848
138
1,714
1,147
839
884
2,134
1,920
1,419
1,697
2,942
3,625
2,283
2,2833,6252,9421,6971,4191,9202,1348848391,1471,7141382,84825,19671002,9283,24587302,8812,5442,0182,0282,1851,9701,8231,9851,5411,6291,1499111,1621,219929594713709599256452475422662740821
   > Long-term Assets 
1,996
0
2,948
3,656
5,160
5,776
5,744
6,792
5,470
2,543
2,099
3,266
9,021
8,906
15,615
15,331
14,909
8,732
9,356
20,686
20,424
19,769
19,243
19,010
19,008
19,080
30,485
0
29,015
27,168
26,770
0
26,059
10,561
8,233
0
7,726
7,166
6,889
3,425
35,814
35,328
34,926
14,422
12,065
10,563
10,913
10,91310,56312,06514,42234,92635,32835,8143,4256,8897,1667,72608,23310,56126,059026,77027,16829,015030,48519,08019,00819,01019,24319,76920,42420,6869,3568,73214,90915,33115,6158,9069,0213,2662,0992,5435,4706,7925,7445,7765,1603,6562,94801,996
       Property Plant Equipment 
1,179
0
1,165
1,141
1,065
994
908
965
899
856
810
1,265
1,312
1,476
4,338
4,447
4,046
3,888
3,779
6,069
5,870
5,372
4,912
4,738
4,778
4,724
6,009
5,550
5,550
4,742
4,499
4,056
4,056
787
786
2,789
652
647
535
448
2,517
2,722
2,157
1,693
2,672
2,792
2,840
2,8402,7922,6721,6932,1572,7222,5174485356476522,7897867874,0564,0564,4994,7425,5505,5506,0094,7244,7784,7384,9125,3725,8706,0693,7793,8884,0464,4474,3381,4761,3121,2658108568999659089941,0651,1411,16501,179
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,131
2,994
3,187
3,187
3,187
12,029
12,029
12,029
12,029
12,029
12,029
12,029
14,158
17,992
17,992
17,257
17,257
17,257
17,257
5,963
3,090
3,090
3,090
3,090
3,090
2,977
22,164
21,703
22,085
0
0
0
0
000022,08521,70322,1642,9773,0903,0903,0903,0903,0905,96317,25717,25717,25717,25717,99217,99214,15812,02912,02912,02912,02912,02912,02912,0293,1873,1873,1872,9943,13100000000000000
       Intangible Assets 
135
0
128
205
244
346
378
325
329
349
366
402
432
451
477
503
534
553
585
1,727
1,679
1,639
1,594
1,503
1,451
1,400
8,356
4,478
4,478
4,276
4,121
4,004
4,004
3,126
3,021
2,895
2,895
2,681
2,563
0
9,500
9,262
9,025
0
0
0
0
00009,0259,2629,50002,5632,6812,8952,8953,0213,1264,0044,0044,1214,2764,4784,4788,3561,4001,4511,5031,5941,6391,6791,7275855535345034774514324023663493293253783462442051280135
       Long-term Assets Other 
682
0
1,655
2,311
3,850
4,436
4,458
5,502
4,242
1,337
923
612
6,302
6,302
6,341
6,340
6,302
460
1,505
520
517
415
412
472
494
678
1,715
749
749
650
651
650
650
593
1,244
997
997
692
645
0
1,633
1,641
1,659
12,729
9,393
7,771
8,073
8,0737,7719,39312,7291,6591,6411,63306456929979971,2445936506506516507497491,7156784944724124155175201,5054606,3026,3406,3416,3026,3026129231,3374,2425,5024,4584,4363,8502,3111,6550682
> Total Liabilities 
12,038
0
20,592
26,097
27,607
28,203
28,095
32,933
28,935
13,324
9,425
9,694
9,448
9,136
13,612
12,551
12,223
13,056
13,662
15,867
15,672
15,076
17,976
16,810
22,440
22,324
22,834
25,456
25,456
24,091
30,637
28,604
28,604
32,175
13,372
7,519
7,519
6,687
4,885
4,368
8,467
5,338
5,304
6,346
10,161
10,024
9,199
9,19910,02410,1616,3465,3045,3388,4674,3684,8856,6877,5197,51913,37232,17528,60428,60430,63724,09125,45625,45622,83422,32422,44016,81017,97615,07615,67215,86713,66213,05612,22312,55113,6129,1369,4489,6949,42513,32428,93532,93328,09528,20327,60726,09720,592012,038
   > Total Current Liabilities 
1,521
0
10,658
4,453
3,080
6,954
10,702
11,772
13,102
12,639
8,078
8,619
2,458
2,372
5,287
4,366
4,080
4,832
6,505
9,865
10,344
10,127
10,620
11,046
8,760
9,111
11,694
19,640
19,640
21,542
28,339
27,293
27,293
31,908
12,675
6,972
6,972
6,481
4,751
4,263
7,788
4,638
4,669
5,431
7,472
7,507
6,693
6,6937,5077,4725,4314,6694,6387,7884,2634,7516,4816,9726,97212,67531,90827,29327,29328,33921,54219,64019,64011,6949,1118,76011,04610,62010,12710,3449,8656,5054,8324,0804,3665,2872,3722,4588,6198,07812,63913,10211,77210,7026,9543,0804,45310,65801,521
       Short-term Debt 
0
0
8,334
100
100
2,739
6,282
6,708
7,520
9,561
6,044
6,022
6,022
0
281
0
0
333
833
1,333
1,833
2,000
2,000
2,000
2,000
2,000
2,000
6,000
6,000
9,438
11,066
2,481
2,481
3,101
2,273
1,277
1,277
840
38
223
678
521
365
331
399
454
550
550454399331365521678223388401,2771,2772,2733,1012,4812,48111,0669,4386,0006,0002,0002,0002,0002,0002,0002,0001,8331,3338333330028106,0226,0226,0449,5617,5206,7086,2822,7391001008,33400
       Accounts payable 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
422
422
2,146
2,674
2,863
2,333
1,412
1,016
1,073
740
1,765
1,040
897
8971,0401,7657401,0731,0161,4122,3332,8632,6742,1464224220000000000000000000000000000000000
       Other Current Liabilities 
1,521
0
2,325
4,353
2,980
4,123
3,998
4,596
4,906
2,759
1,819
2,398
2,371
2,341
4,622
3,822
3,813
4,117
4,498
7,701
7,881
7,704
8,410
8,257
8,328
6,978
9,585
0
13,124
10,100
14,864
0
22,639
27,185
8,795
90
4,478
1,988
1,052
694
4,352
1,685
1,773
4,286
5,236
5,941
5,174
5,1745,9415,2364,2861,7731,6854,3526941,0521,9884,478908,79527,18522,639014,86410,10013,12409,5856,9788,3288,2578,4107,7047,8817,7014,4984,1173,8133,8224,6222,3412,3712,3981,8192,7594,9064,5963,9984,1232,9804,3532,32501,521
   > Long-term Liabilities 
10,517
0
9,934
21,643
24,527
21,250
17,393
21,161
15,832
686
1,347
1,075
6,990
6,764
8,325
8,185
8,142
8,224
7,157
6,002
5,328
4,949
7,356
5,764
13,680
13,213
11,140
0
5,816
2,549
2,298
0
1,311
267
697
0
547
206
134
0
679
700
635
915
2,689
2,517
2,506
2,5062,5172,689915635700679013420654706972671,31102,2982,5495,816011,14013,21313,6805,7647,3564,9495,3286,0027,1578,2248,1428,1858,3256,7646,9901,0751,34768615,83221,16117,39321,25024,52721,6439,934010,517
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
634
634
1,967
1,967
0
1
0
49
834
780
728
728780834490101,9671,967634634000000000000000000000000000000000000
> Total Stockholder Equity
-6,736
0
-16,484
-19,065
-19,241
-20,814
-20,157
-23,981
-21,524
-6,869
4,882
45,463
43,635
40,463
38,022
34,554
30,972
26,772
22,318
33,017
28,297
29,159
27,847
25,624
20,925
18,625
31,136
0
26,765
17,280
9,248
0
6,802
4,940
7,464
0
7,385
5,101
4,805
3,980
63,888
60,063
55,916
31,290
22,368
16,787
13,840
13,84016,78722,36831,29055,91660,06363,8883,9804,8055,1017,38507,4644,9406,80209,24817,28026,765031,13618,62520,92525,62427,84729,15928,29733,01722,31826,77230,97234,55438,02240,46343,63545,4634,882-6,869-21,524-23,981-20,157-20,814-19,241-19,065-16,4840-6,736
   Common Stock
1
0
1
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
0
3
3
3
0
3
6
0
0
0
0
0
0
3
3
3
3
3
3
1
13333330000006303330222222111111111110000000101
   Retained Earnings -97,244-93,781-87,976-78,813-53,967-49,506-45,320-37,954-168,656-167,303-164,424-164,424-164,131-166,106-157,716-157,716-153,951-145,432-134,834-134,834-126,933-126,300-123,534-113,954-111,178-107,433-103,405-98,151-92,438-87,226-82,246-77,967-72,794-67,997-63,810-61,325-58,800-55,734-46,592-48,935-44,890-45,202-43,341-42,269-39,2250-22,382
   Accumulated Other Comprehensive Income 
-1,300
0
0
-1,656
0
0
0
-1,994
0
0
0
-2,305
-2,305
0
0
-2,885
-2,885
0
0
-4,388
-4,388
0
0
-6,356
-6,356
0
0
-8,155
-8,155
0
0
-9,181
-9,181
0
0
-495
-495
0
0
-223
-223
-1
16
-74
-70
-62
74
74-62-70-7416-1-223-22300-495-49500-9,181-9,18100-8,155-8,15500-6,356-6,35600-4,388-4,38800-2,885-2,88500-2,305-2,305000-1,994000-1,65600-1,300
   Capital Surplus 00000000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000
   Other Stockholders Equity 
16,945
0
22,740
24,860
24,100
24,388
24,733
26,947
25,068
48,865
63,681
109,092
107,445
108,460
110,815
115,405
113,217
113,997
114,755
135,555
131,701
136,590
139,023
145,932
144,457
144,923
158,067
0
169,751
162,709
163,196
0
173,696
171,040
171,595
0
172,304
172,404
173,461
4,203
109,205
109,567
109,864
110,174
110,411
110,627
111,009
111,009110,627110,411110,174109,864109,567109,2054,203173,461172,404172,3040171,595171,040173,6960163,196162,709169,7510158,067144,923144,457145,932139,023136,590131,701135,555114,755113,997113,217115,405110,815108,460107,445109,09263,68148,86525,06826,94724,73324,38824,10024,86022,740016,945



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2021-12-31)

Gross Profit (+$)
totalRevenue1,148
Cost of Revenue-1,847
Gross Profit-699-699
 
Operating Income (+$)
Gross Profit-699
Operating Expense-12,697
Operating Income-15,706-13,396
 
Operating Expense (+$)
Research Development4,273
Selling General Administrative8,424
Selling And Marketing Expenses8,424
Operating Expense12,69721,121
 
Net Interest Income (+$)
Interest Income-
Interest Expense--372
Net Interest Income-372372
 
Pretax Income (+$)
Operating Income-15,706
Net Interest Income-372
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-18,575-12,837
EBIT - interestExpense = -40,859
-18,575
-41,231
Interest Expense-372
Earnings Before Interest and Taxes (ebit)-41,231-18,947
Earnings Before Interest and Taxes (ebitda)-40,177
 
After tax Income (+$)
Income Before Tax-18,575
Tax Provision-0
Net Income From Continuing Ops-18,575-18,575
Net Income-40,859
Net Income Applicable To Common Shares-40,859
 
Non-recurring Events
Discontinued Operations-22,284
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses14,544
Total Other Income/Expenses Net-2,869372
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.
Penke's Market Notifications
POLY.XETRA
9 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of POLY.XETRA.

POLY.XETRA Daily Candlestick Chart
ENTEL.SN
12 minutes ago

I found you a Golden Cross on the daily chart of ENTEL.SN.

ENTEL.SN Daily Candlestick Chart
CENCOSUD.SN
13 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of CENCOSUD.SN.

CENCOSUD.SN Daily Candlestick Chart
ANTARCHILE.SN
13 minutes ago

I found you a Death Cross on the daily chart of ANTARCHILE.SN.

ANTARCHILE.SN Daily Candlestick Chart
3BBE.XETRA
14 minutes ago

I found you a STOCH Bullish Hidden Divergence on the daily chart of 3BBE.XETRA.

3BBE.XETRA Daily Candlestick Chart
FORUS.SN
14 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of FORUS.SN.

FORUS.SN Daily Candlestick Chart
NGA1L.MI
15 minutes ago

I found you a RSI Bullish Reversal Divergence on the daily chart of NGA1L.MI.

NGA1L.MI Daily Candlestick Chart
3CRE.XETRA
15 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of 3CRE.XETRA.

3CRE.XETRA Daily Candlestick Chart
GLGI.OTCQB
17 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of GLGI.OTCQB.

GLGI.OTCQB Daily Candlestick Chart
CCMCUA.SW
21 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of CCMCUA.SW.

CCMCUA.SW Daily Candlestick Chart
AUVI.NASDAQ
22 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of AUVI.NASDAQ.

AUVI.NASDAQ Daily Candlestick Chart
AUUD.NASDAQ
22 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of AUUD.NASDAQ.

AUUD.NASDAQ Daily Candlestick Chart
AUPH.NASDAQ
23 minutes ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of AUPH.NASDAQ.

AUPH.NASDAQ Daily Candlestick Chart
WIB.STU
32 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of WIB.STU.

WIB.STU Daily Candlestick Chart
WFSTF.PINK
32 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of WFSTF.PINK.

WFSTF.PINK Daily Candlestick Chart
WEDXF.PINK
33 minutes ago

I found you a Golden Cross on the daily chart of WEDXF.PINK.

WEDXF.PINK Daily Candlestick Chart
WCIG.PINK
34 minutes ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of WCIG.PINK.

WCIG.PINK Daily Candlestick Chart
VISA.NEO
40 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of VISA.NEO.

VISA.NEO Daily Candlestick Chart
BOTZ.SW
48 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of BOTZ.SW.

BOTZ.SW Daily Candlestick Chart
UPG.BR
48 minutes ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of UPG.BR.

UPG.BR Daily Candlestick Chart
ICC.MI
53 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of ICC.MI.

ICC.MI Daily Candlestick Chart
CBUS5.SW
53 minutes ago

I found you a Golden Cross on the daily chart of CBUS5.SW.

CBUS5.SW Daily Candlestick Chart
TSLA.NEO
54 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of TSLA.NEO.

TSLA.NEO Daily Candlestick Chart
GASE.PINK
55 minutes ago

I found you a RSI Bullish Reversal Divergence on the daily chart of GASE.PINK.

GASE.PINK Daily Candlestick Chart